Re: Farmas USA
CELG
Para lo bueno o para lo malo en 2 semanas tenemos ASCO, ahí presentará como siempre una buena bateria de datos:
At the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in June, data presentations are expected to include:
- Updated durability and safety data from the pivotal TRANSCEND NHL-001 trial evaluating liso-cel (JCAR017) in patients with relapsed or refractory aggressive non-Hodgkin lymphoma (NHL). In addition, the pivotal TRANSCEND NHL-001 trial completed enrollment in April.
- In collaboration with partner bluebird bio, updated data from the CRB-401 phase I trial evaluating bb2121 in patients with relapsed and/or refractory multiple myeloma (RRMM).
- Results from the phase III OPTIMISMM® trial evaluating POMALYST® in combination with bortezomib and dexamethasone (PVd) in patients with second-line multiple myeloma.
- Results from the phase III RELEVANCE® trial with REVLIMID® in combination with rituximab (R²) in patients with previously untreated follicular lymphoma (FL).
- Primary progression-free survival (PFS) and safety analysis from the Genentech-sponsored phase III IMpower131 trial evaluating atezolizumab plus chemotherapy (carboplatin and ABRAXANE®) as first-line treatment in patients with advanced squamous non-small cell lung cancer (NSCLC).